(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the Proffered Paper session 2: GU, non-prostate. Dr. Shilpa Gupta discussed the presentations from Drs Andromachi Kougioumtzopoulou and Jens Bedke.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a session focusing on rare genitourinary cancers. Professor Syed Hussain provided an overview of the histologic subtypes (i.e., variants) of bladder cancer.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a proffered paper session for non-prostate genitourinary malignancies. Dr. Hiroshi Kitamura presented the results of JCOG1019, an open-label, non-inferiority, randomized phase III trial comparing the effectiveness of watchful waiting and intravesical Bacillus Calmette-Guérin (BCG) in patients with high-grade T1 bladder cancer with evidence of pT0 disease on the repeat transurethral resection specimen.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the Proffered Paper session 2: GU, non-prostate. Dr. Andromachi Kougioumtzopoulou presented the findings of a a phase II, randomized study by the Hellenic GU Cancer Group exploring Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer, not undergoing cystectomy.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the Proffered Paper session 2: GU, non-prostate. Dr. Jens Bedke presented the results of an exploratory analysis of the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma, exploring health-related quality of life.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the presentation of Poster 1618. Dr. Anis Hamid discussed the clinical prognostic factors within the high-volume subgroup of metastatic hormone-sensitive prostate cancer (mHSPC) in the ENZAMET (ANZUP 1304) study.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the session presentation of Poster 2016. Dr. Cora N. Sternberg discussed the evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant therapy.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the presentation of the trial in progress 1662. Dr. Qian Qin presented HARMONY: A phase II study of niraparib/abiraterone acetate plus prednisone for Hispanic/Latino and non-Hispanic Black patients with metastatic hormone-sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of the poster 1615. Dr. Susan Halabi presented a new prognostic model of overall survival in patients with metastatic hormone sensitive prostate cancer (mHSPC).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of Poster 1701. Dr. Liangyou Gu presented the results of NEOTAX: a Phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava (IVC) tumor thrombus.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a genitourinary cancers poster session. Dr. Hedyeh Ebrahimi presented the results of a real-world study evaluating the characteristics and outcomes of patients with muscle-invasive urothelial carcinoma (MIUC) receiving nivolumab +/- neoadjuvant chemotherapy.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a genitourinary cancers poster session. Dr. Aleksander Antoniewicz presented the results of an interim analysis of a phase I study evaluating trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of Poster 2013. Dr. Gregor Duwe presented the first preliminary results of artificial intelligence (AI) generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of poster 1611. Dr. Kim Chi discussed the hematologic impact of [177Lu]Lu-PSMA-617 versus androgen receptor pathway inhibitor (ARPI) change in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PSMAfore trial.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a session on future therapy targets for metastatic prostate cancer patients. Dr. Wilbert Zwart discussed targeting epigenetic pathways as a potential therapeutic target for metastatic prostate cancer.

(UroToday.com) The 2024 ESMO annual meeting included a session highlighting urothelial carcinoma trials in progress, with Dr. Tian Zhang discussing STAR-EV, a phase I/II study of stereotactic treatment with neoadjuvant radiotherapy and enfortumab vedotin for localized cisplatin ineligible, muscle invasive bladder cancer. Urothelial cancer is the 9^th most common cancer worldwide, with more than 610,000 people diagnosed per year. Muscle invasive bladder cancer needs more treatment options, and up to 50% of patients with muscle invasive bladder cancer cannot receive cisplatin-based chemotherapy. Definitive treatment of muscle invasive bladder cancer depends on neoadjuvant chemotherapy and surgery, or trimodality therapy with maximal resection followed by chemoradiation therapy.

(UroToday.com) The 2024 ESMO annual meeting included a session on urothelial carcinoma, featuring a presentation by Dr. Dag Rune Stormoen discussing the genetic profile in early and late stage urothelial tract cancer. Urothelial carcinoma is the 13^th most lethal cancer worldwide, with ongoing gaps in the knowledge of the mutational landscape in patients with advanced disease after multiple lines of prior treatment. This study presented at ESMO 2024 compared the genomic, transcriptomics, and targeted treatment options between metastatic urothelial carcinoma patients treated with multiple lines of therapy to newly diagnosed, untreated muscle invasive bladder cancer.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussant presentation by Dr. Christopher Sweeney discussing two abstracts including “CC-94676-PCA-001: Clinical activity of BMS-986365, a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with mCRPC” by Dr. Dana Rathkopf and “INSPIRE: Phase 2 trial of Nivolumab 3mg/kg and ipilimumab 1mg/kg in molecularly selected patients with mCRPC” by Dr. Niven Mehra. Dr. Sweeney started his discussant presentation by highlighting key features of metastatic CRPC treatment in 2024 and beyond:

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Guarionex DeCastro presented the results of a phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussant presentation by Dr. Deborah Mukherji discussing two abstracts including “RAPSON: Open-label, multicenter randomized trial of Radium-223 -> docetaxel versus docetaxel -> Radium-223 sequence in mCRPC with prospective biomarker evaluation” by Dr. Vincenza Conteduca and “Adding metformin to ADT for patients with mHSPC: Overall survival results from the multi-arm, multi-stage randomized platform trial STAMPEDE” by Dr. Silke Gillessen.